'No one has to watch someone they love suffer...': Bill Gates sees hope in the fight against Alzheimer's, and it's deeply personal, 5 years after his father's loss
Bill Gates sees hope in the fight against Alzheimer's: It's deeply personal; 5 years after his father's loss
Five years ago,
Bill Gates
experienced one of the most severe personal losses of his life: seeing his father, William H. Gates Sr., suffer through the heartless advance of Alzheimer's disease. In a stunning new essay on Gates Notes, the Microsoft co-founder vividly remembers,
'Watching my brilliant, loving father go downhill and disappear was a brutal experience.'
That experience has since driven his dedication to fighting this ruinous condition, not only through philanthropy, but through sheer technological and scientific push.
On the cutting edge of Alzheimer's research today, Bill Gates finds reasons for real hope. Following his visit to Indiana University's School of Medicine in 2024, he was invigorated by what he described as "the latest breakthrough": blood tests that could diagnose Alzheimer's years before signs of the disease show up. Combined with recently approved medications that slightly slow the march of the disease, Gates feels the world is moving closer to a day when no one will have to suffer the agony of losing a loved one. As he states,
'We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.'
Bill Gates' fight against Alzheimer's is deeply personal
Alzheimer's is not only a health or numerical problem for Bill Gates—it's personal. More than 7 million Americans have Alzheimer's today, including almost 1 in 9 individuals aged 65 and older. And although treatment advances have seemed glacial, Gates's path has been a witness to love-driven perseverance. Spurred on by his father's pain and his call to action, Gates has emerged as one of the most vocal voices urging more money, improved tools, and increased urgency in Alzheimer's research.
Bill Gates on Alzheimer's: 'This simple blood test could change everything'
When Gates visited IU's School of Medicine, he discovered a revolution in the making for Alzheimer's care: blood tests to diagnose Alzheimer's. The tests quantify the amount and ratio of amyloid plaques and tau proteins—Alzheimer's signatures in the brain, years before full-blown symptoms emerge.
Early detection
: Researchers now recognise that Alzheimer's disease starts as much as 20 years before the development of clinical symptoms.
Scalable screening
: Rather than expensive PET scans or invasive cerebrospinal fluid analysis, a routine blood draw might become a standard part of checkups.
Proactive intervention
: Precocious diagnosis by blood tests might lead to treatments that halt intellectual decline before such damage to the brain is permanent.
Gates calls these advances a "game-changer"—not only for researchers, but also for families and caregivers who have felt helpless against the advancement of the disease.
Two FDA-approved drugs: A modest win with massive implications
Encouraging therapy isn't confined to diagnosis. In the past few months, the US Food and Drug Administration has licensed two novel Alzheimer's medications that have been demonstrated to moderately decelerate disease exacerbation. Though not cures, these medications constitute a significant turning point—from symptom treatment to addressing core pathology.
Proof of concept
: These approvals demonstrate proof of the amyloid hypothesis and lead to further innovation.
Strengthened pipeline
: Researchers and companies are increasingly likely to invest in comparable treatments, converting optimism into economic as well as health momentum.
Gates's enthusiasm is palpable:
'When combined with early diagnostics, I really am excited about the future of treating this disease.'
Bill Gates warns: Alzheimer's treatment progress at risk without public funding
Despite advances in science, Gates warns of an impending crisis: dwindling public funding. Over the past few months, budgets for the National Institutes of Health and connected research agencies have been trimmed, just when momentum is gaining steam.
He argues:
This is exactly when investment is most needed.
Government grants support large-scale clinical trials and early-stage science that private philanthropy cannot support on its own.
Scaling up biotech instruments such as blood tests and treatments necessitates infrastructures which only governments can develop and sustain.
'If we pull back now, all this progress could grind to a halt—and no private initiative can fill that gap,'
Gates writes.
Bill Gates sees a turning point: 'Alzheimer's no longer feels hopeless'
Over the past few years, Alzheimer's seemed like a black hole of despair—until now. Gates spotlights some of the reasons why the tide is turning:
Technological convergence
: Biomarker analysis enabled by AI, cheap genomic technologies, and wearable tech are improving detection accuracy and affordability.
Early diagnosis culture
: Screening for Alzheimer's might soon become part of normal healthcare, along with blood pressure and cholesterol tests.
Global advocacy
: An expanding group of caregivers, scientists, business leaders, and foundations making a difference.
Tangible progress
: From tests to therapies, the gradual trickle of breakthroughs is turning into a flood, exciting scientists as well as sufferers.
Gates's vision: A future free from Alzheimer's tragedy
For Bill Gates, fighting Alzheimer's is not about making headlines—it's about saving families the emotional anguish he suffered personally. He dreams of a world where:
Early detection technologies detect the disease years before symptoms arise.
Targeted treatments halt or slow the disease, maintaining quality of life.
Funding and public support fuel a massive research pipeline.
In his most passionate sentence, Gates pleads: 'We are on the cusp of turning the tide against dementia.' But he also warns that urgency must be followed by action—more money, more research, more courage in science.
Also read |
Jeff Bezos' Indian Creek property just got a $105 million neighbour; here's who bought the 'billionaire bunker' land
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Time of India
8 hours ago
- Time of India
Algebra, philosophy and…: These AI chatbot queries cause most harm to environment, study claims
Representative Image Queries demanding complex reasoning from AI chatbots, such as those related to abstract algebra or philosophy, generate significantly more carbon emissions than simpler questions, a new study reveals. These high-level computational tasks can produce up to six times more emissions than straightforward inquiries like basic history questions. A study conducted by researchers at Germany's Hochschule München University of Applied Sciences, published in the journal Frontiers (seen by The Independent), found that the energy consumption and subsequent carbon dioxide emissions of large language models (LLMs) like OpenAI's ChatGPT vary based on the chatbot, user, and subject matter. An analysis of 14 different AI models consistently showed that questions requiring extensive logical thought and reasoning led to higher emissions. To mitigate their environmental impact, the researchers have advised frequent users of AI chatbots to consider adjusting the complexity of their queries. Why do these queries cause more carbon emissions by AI chatbots In the study, author Maximilian Dauner wrote: 'The environmental impact of questioning trained LLMs is strongly determined by their reasoning approach, with explicit reasoning processes significantly driving up energy consumption and carbon emissions. We found that reasoning-enabled models produced up to 50 times more carbon dioxide emissions than concise response models.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Americans Are Freaking Out Over This All-New Hyundai Tucson (Take a Look) Smartfinancetips Learn More Undo The study evaluated 14 large language models (LLMs) using 1,000 standardised questions to compare their carbon emissions. It explains that AI chatbots generate emissions through processes like converting user queries into numerical data. On average, reasoning models produce 543.5 tokens per question, significantly more than concise models, which use only 40 tokens. 'A higher token footprint always means higher CO2 emissions,' the study adds. The study highlights that Cogito, one of the most accurate models with around 85% accuracy, generates three times more carbon emissions than other similarly sized models that offer concise responses. 'Currently, we see a clear accuracy-sustainability trade-off inherent in LLM technologies. None of the models that kept emissions below 500 grams of carbon dioxide equivalent achieved higher than 80 per cent accuracy on answering the 1,000 questions correctly,' Dauner explained. Researchers used carbon dioxide equivalent to measure the climate impact of AI models and hope that their findings encourage more informed usage. For example, answering 600,000 questions with DeepSeek R1 can emit as much carbon as a round-trip flight from London to New York. In comparison, Alibaba Cloud's Qwen 2.5 can answer over three times more questions with similar accuracy while producing the same emissions. 'Users can significantly reduce emissions by prompting AI to generate concise answers or limiting the use of high-capacity models to tasks that genuinely require that power,' Dauner noted. AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hans India
13 hours ago
- Hans India
ZeroHarm Eyes Rs 150 Crore Milestone by FY 2025 -'26, Accelerates Global Expansion into GCC
ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is set to accelerate its global footprint with a focused expansion into the GCC markets, including the UAE and the broader Middle East. Following a remarkable 10× revenue growth over the past two years and operating at a healthy ~20% EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by strong domestic and global momentum and increasing traction in the United States, which now contributes nearly 30% of its overall revenue. At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. This breakthrough, backed by granted patents and deep R&D, makes ZeroHarm the first Indian company to bring pharmaceutical nanotech into nutraceuticals at scale. ZeroHarm's US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products, setting it apart in a market rife with unverified health claims. Today, the company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support, with over million units sold across India to date. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can produce up to ₹250 crore worth of finished goods annually, making it one of the few Indian nutraceutical brands with true end-to-end production capabilities. To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States, enhancing local supply chain efficiency, fast-tracking formulation innovation, and enabling closer clinical and regulatory collaborations in key global markets. The U.S. infrastructure also gives ZeroHarm a significant strategic edge in developed markets, where stringent compliance standards often limit entry for Indian nutraceutical brands reliant on contract manufacturing. 'The global nutraceutical market is shifting, consumers are demanding not just clean labels, but clinical credibility. At ZeroHarm, we've combined deep R&D with pharma-grade nanotechnology to raise the bar for efficacy, safety, and transparency in preventive wellness. Our entry into the GCC is a natural extension of the trust we've built in India and the U.S., and a significant step toward making evidence-backed, plant-based therapeutics accessible to global consumers,' said Sachin Darbarwar, Founder & CEO, ZeroHarm Sciences. With distribution agreements and regulatory filings already underway, the company will also launch in the UK aside from the GCC markets by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.
